Dr. Bray Links

Monday, June 25, 2018

Combo antibiotic found inferior for MDR bloodstream infections | CIDRAP

The results of a large, international randomized trial indicate that the use of a combination therapy being investigated as a potential alternative to carbapenem antibiotics should be avoided in patients with certain multidrug-resistant bloodstream infections (BSIs), because of increased risk of mortality.

The findings of the MERINO Trial, presented this week at the 28th annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID), showed that the combination antibiotic piperacillin/tazobactam is inferior to meropenem for treating BSIs caused by third-generation cephalosporin-resistant Escherichia coli or Klebsiella pneumoniae. The number of patients on piperacillin/tazobactam who died at the 30-day mark was more than three times the number who died in the meropenem arm.

http://www.cidrap.umn.edu/news-perspective/2018/04/combo-antibiotic-found-inferior-mdr-bloodstream-infections

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.